Policy Statement

Magnetoencephalography/magnetic source imaging as part of the preoperative evaluation of patients with drug-resistant epilepsy (seizures refractory to at least 2 first-line anticonvulsants) may be considered medically necessary when standard techniques, magnetic resonance imaging (MRI) and electroencephalogram (EEG), do not provide satisfactory localization of epileptic lesion(s).

Magnetoencephalography/magnetic source imaging for the purpose of determining the laterality of language function, as a substitute for the Wada test, may be considered medically necessary in patients being prepared for surgery for any of the following indications:

- Brain tumors
- Epilepsy
- Other indications requiring brain resection

Magnetoencephalography/magnetic source imaging is considered investigational for all other indications.

Policy Guidelines

Coding

The following CPT codes specifically describe magnetoencephalography:

- **95965**: Magnetoencephalography (MEG), recording and analysis, for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)
- **95966**: Magnetoencephalography (MEG), recording and analysis, for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)
- **95967**: Magnetoencephalography (MEG), recording and analysis, for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)

Description

Magnetoencephalography (MEG) is a noninvasive functional imaging technique that records weak magnetic forces. When this information is superimposed on an anatomic image of the brain, typically a magnetic resonance imaging scan, the image is referred to as magnetic source imaging (MSI). MSI has been used to localize epileptic foci and to identify “eloquent” areas of the brain for neurosurgical planning.

Related Policies

- Functional Magnetic Resonance Imaging of the Brain

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

The Food and Drug Administration regulates MEG devices as class II devices cleared for marketing through the 510(k) process. The Food and Drug Administration product codes OLX and OXY are used to identify the different components of the devices. OLX-coded devices are source localization software for electroencephalography or MEG; the software correlates the electrical activity of the brain using various neuroimaging modalities. This code does not include electrodes, amplitude-integrated electroencephalograph, automatic event-detection software used as the only or final electroencephalograph analysis step, electroencephalography software with comparative databases (normal or otherwise), or electroencephalography software that outputs an index, diagnosis, or classification.

OLY-coded devices are magnetoencephalographs that acquire, display, store, and archive biomagnetic signals produced by electrically active nerve tissue in the brain to provide information about the location of active nerve tissue responsible for certain brain functions relative to brain anatomy. This includes the magnetoencephalograph recording device (hardware, basic software).

The intended use of these devices is to “non-invasively detect and display biomagnetic signals produced by electrically active nerve tissue in the brain. When interpreted by a trained clinician, the data enhance the diagnostic capability by providing useful information about the location relative to brain anatomy of active nerve tissue responsible for critical brain functions.” More recent approval summaries add: “MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain when used in conjunction with evoked response averaging devices. MEG is also used to noninvasively locate regions of epileptic activity within the brain. The localization information provided by MEG may be used, in conjunction with other diagnostic data, in neurosurgical planning.”

The MagView Biomagnetometer System (Tristan Technologies) has the unique intended use for patient populations who are neonates and infants and those children with head circumferences of 50 cm or less.

Table 1 summarizes relevant MEG devices (hardware, software).

### Table 1. Magnetoencephalography Devices Cleared by the FDA (Product Codes OLX and OLY)

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuromagneometer</td>
<td>Biomagnetic Technologies</td>
<td>Feb 1986</td>
<td>K854466</td>
</tr>
<tr>
<td>700 Series Biomagnetometer</td>
<td>Biomagnetic Technologies</td>
<td>Jun 1990</td>
<td>K901215</td>
</tr>
<tr>
<td>Neuromag-122</td>
<td>Philips Medical Systems</td>
<td>Oct 1996</td>
<td>K962764</td>
</tr>
<tr>
<td>Magnes 2500 Wh Biomagnetometer</td>
<td>Biomagnetic Technologies</td>
<td>May 1997</td>
<td>K962317</td>
</tr>
<tr>
<td>CTF Systems, Whole-Cortex Meg System</td>
<td>CTF Systems</td>
<td>Nov 1997</td>
<td>K971329</td>
</tr>
<tr>
<td>Magnes II Biomagnetometer</td>
<td>BioMedical Technologies</td>
<td>May 1998</td>
<td>K941553</td>
</tr>
<tr>
<td>Image Vue EEG</td>
<td>Sam Technology</td>
<td>Aug 1988</td>
<td>K980477</td>
</tr>
<tr>
<td>Electroencephalograph Software eemagine</td>
<td>eemagine Medical Imaging</td>
<td>Oct 2000</td>
<td>K002631</td>
</tr>
<tr>
<td>Cuny Multimodal Neuroimaging Software</td>
<td>Neurosoft</td>
<td>Feb 2001</td>
<td>K001781</td>
</tr>
<tr>
<td>Neurosoft's Source</td>
<td>Neurosoft</td>
<td>Sep 2001</td>
<td>K011241</td>
</tr>
<tr>
<td>Megvision Model Eq1000c Series</td>
<td>Eagle Technology</td>
<td>Mar 2004</td>
<td>K040051</td>
</tr>
<tr>
<td>Elekta Oy</td>
<td>Elekta NeuroMag Oy</td>
<td>Aug 2004</td>
<td>K041264</td>
</tr>
<tr>
<td>MaxInsight</td>
<td>eemagine Medical Imaging</td>
<td>Jul 2007</td>
<td>K070358</td>
</tr>
</tbody>
</table>
### Magnetoencephalography/Magnetic Source Imaging

**Device** | **Manufacturer** | **Date Cleared** | **510(k) No.**
--- | --- | --- | ---
Elekta Neuromag With Maxfilter | Elekta Neuromag Oy | Oct 2010 | K091393
Geosource | Electrical Geodesics | Dec 2010 | K092844
Babymeg Biomagnetometer System (also called Artemis 123 Biomagnetometer) | Tristan Technologies | Jul 2014 | K133419
MagView Biomagnetometer System | Tristan Technologies | Apr 2016 | K152184

**EEG**: electroencephalogram; **FDA**: Food and Drug Administration.

In 2000, Biomagnetic Technologies acquired Neuromag and began doing business as 4-D Neuroimaging. The latter company ceased operations in 2009.

### Rationale

**Background**

**Magnetoencephalography**

Magnetoencephalography (MEG) is a noninvasive functional imaging technique that records weak magnetic forces associated with brain electrical activity. Using mathematical modeling, recorded data are then analyzed to provide an estimated location of electrical activity. This information can be superimposed on an anatomic image of the brain, typically a magnetic resonance imaging (MRI) scan, to produce a functional/anatomic image of the brain, referred to as magnetic source imaging (MSI). The primary advantage of MSI is that, while conductivity and thus measurement of electrical activity as recorded by electroencephalogram is altered by the surrounding brain structures, magnetic fields are not. Therefore, MSI permits a high-resolution image.

Detection of weak magnetic fields requires gradiometer detection coils coupled to a superconducting quantum interference device, which requires a specialized room shielded from other magnetic sources. Mathematical modeling programs based on idealized assumptions are then used to translate detected signals into functional images. In its early evolution, clinical applications were limited by the use of only 1 detection coil requiring lengthy imaging times, which, because of body movement, also were difficult to match with the MRI. However, more recently, the technique has evolved to multiple detection coils in an array that can provide data more efficiently over a wide extracranial region.

**Applications**

One clinical application is the localization of epileptic foci, particularly for screening of surgical candidates and surgical planning. Alternative techniques include MRI, positron emission tomography, or single-photon emission computed tomography scanning. Anatomic imaging (i.e., MRI) is effective when epilepsy is associated with a mass lesion, such as a tumor, vascular malformation, or hippocampal atrophy. If an anatomic abnormality is not detected, patients may undergo a positron emission tomography scan. In a small subset of patients, extended electrocorticography or stereotactic electroencephalography with implanted electrodes is considered the criterion standard for localizing epileptogenic foci. MEG/MSI have principally been investigated as a supplement to or an alternative to invasive monitoring.

Another clinical application is the localization of the pre- and postcentral gyri as a guide to surgical planning in patients scheduled to undergo neurosurgery for epilepsy, brain neoplasms, arteriovenous malformations, or other brain lesions. These gyri contain the "eloquent" sensorimotor areas of the brain, the preservation of which is considered critical during any type of brain surgery. In normal situations, these areas can be identified anatomically by MRI, but frequently, anatomy is distorted by underlying disease processes. In addition, the location of eloquent functions varies, even among healthy people. Therefore, localization of the eloquent cortex often requires such intraoperative invasive functional techniques as cortical stimulation with the patient under local anesthesia or somatosensory-evoked responses on extended electrocorticography. Although these techniques can be done at the same time as the planned surgery, the invasiveness of the procedures makes them inappropriate for routine screening in large numbers of patients.

Reproduction without authorization from Blue Shield of California is prohibited.
Resection, they are cumbersome and can add up to 45 minutes of anesthesia time. Furthermore, these techniques can sometimes be limited by the small surgical field. A preoperative test, which is often used to localize the eloquent hemisphere, is the Wada test. MEG/MSI has been proposed as a substitute for the Wada test.

**Literature Review**
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Localization of Seizure Foci**

**Clinical Context and Test Purpose**
The purpose of magnetoencephalography (MEG) and magnetic source imaging (MSI) in the mapping of epileptic foci is to facilitate surgical treatment planning for persons with drug-resistant epilepsy.

The question addressed in this evidence review is: Does the use of MEG/MSI enhance localization of epileptic foci in conjunction with other noninvasive testing or replace invasive testing and, thus, result in changes in clinical management and improvement in health outcomes?

The following PICOTS were used to select literature to inform this review.

**Patients**
The relevant population of interest is patients with drug-resistant epilepsy who are being evaluated for resective surgery.

**Interventions**
The intervention of interest is MEG/MSI used to map epileptic foci. MEG/MSI is primarily used as a preoperative adjunct to other noninvasive tests used in clinical practice for epileptic foci localization. These tests include electroencephalography (EEG), magnetic resonance imaging, positron emission tomography (PET), and single-photon emission computerized tomography.

**Comparators**
The following practice is currently being used to make decisions about managing drug-resistant epilepsy: standard evaluation for seizure focus localization.

**Outcomes**
Outcomes of interest are diagnostic accuracy (e.g., test sensitivity and specificity) and clinical utility (e.g., consideration of avoidance of invasive testing).

**Timing**
MEG/MSI is used when evaluating a patient with drug-resistant epilepsy for interventional surgery.

**Setting**
MEG/MSI is administered in an interdisciplinary specialty care setting.
Technically Reliable
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

This section of the review is based on a TEC Special Report (2008) that reviewed the evidence on MEG for localization of epileptic lesions. MEG has been proposed as a method for localizing seizure foci for patients with normal or equivocal magnetic resonance imaging and negative video-EEG examinations, so-called “nonlesional” epilepsy. Such patients often undergo MEG, PET, or ictal single-photon emission computed tomography to localize the seizure focus. They then often undergo invasive intracranial EEG (IC-EEG), a surgical procedure in which electrodes are inserted next to the brain. Definitive proof that MEG is effective would be comparative evidence that when compared with not using MEG, it improved patient outcomes. Such improvement in outcomes would include more patients being rendered seizure-free, use of a less invasive and morbid diagnostic workup, and overall improved patient outcomes. This is a complicated array of outcomes that have not been thoroughly evaluated in a comprehensive manner. Because MEG is used to make decisions regarding further diagnostic testing, which may affect the decision to have surgery and the extent of surgery, solely examining surgical outcomes excludes the assessment of outcomes of patients who did not have surgery.

Ideally, a randomized trial comparing the outcomes of patients who receive MEG as part of their diagnostic workup compared with patients who do not receive MEG could determine whether MEG improves patient outcomes. However, almost all of the studies evaluating MEG have been retrospective, where MEG, other tests, and surgery have been selectively applied to patients. Because patients often drop out of the diagnostic process before having IC-EEG, and many patients ultimately do not undergo surgery, most studies of associations between diagnostic tests and between diagnostic tests and outcomes are biased by selection and ascertainment biases. For example, studies that evaluate the correlation between MEG and IC-EEG invariably do not account for the fact that MEG information was sometimes used to deselect a patient from undergoing IC-EEG. In addition, IC-EEG findings only imperfectly correlate with surgical outcomes, meaning that it is an imperfect reference standard.

Numerous studies have shown associations between MEG findings and other noninvasive and invasive diagnostic tests, including IC-EEG, and between MEG findings and surgical outcomes. However, such studies do not allow any conclusions on whether MEG added incremental information to aid the management of such patients and whether patients’ outcomes were improved as a result of the additional diagnostic information.

A representative study of MEG by Knowlton et al (2008) demonstrated many of the problematic issues of evaluating MEG. In this study of 160 patients with nonlesional epilepsy, all had MEG, but only 72 proceeded to IC-EEG. The calculations of diagnostic characteristics of MEG are biased by incomplete ascertainment of the reference standard. However, even examining the diagnostic characteristics of MEG using the 72 patients who underwent IC-EEG, sensitivities and specificities were well below 90%, indicating the likelihood of both false-positive and false-negative studies. Predictive values based on these sensitivities and specificities mean that MEG can neither rule in nor rule out a positive IC-EEG and that MEG cannot be used as a triage test before IC-EEG to avoid potential morbidity in a subset of patients.

One study more specifically addressed whether MEG can improve the yield of IC-EEG, thus, allowing more patients to receive surgery. In another study by Knowlton et al (2009), MEG results modified the placement of electrodes in 18 (23%) of 77 patients who were recommended to
have IC-EEG. Seven (39%) of 18 patients had positive intracranial seizure recordings involving additional electrode placement because of MEG results. It was concluded that 4 (5%) patients were presumed to have had surgery modified as a result of the effect of MEG electrode placement.

**Section Summary: Clinically Valid**

There are no clinical trials or other high-quality studies demonstrating the diagnostic accuracy of MEG in determining the location of seizure foci. Available evidence on diagnostic accuracy is limited by ascertainment and selection biases because MEG findings were used to select and deselect patients in the diagnostic pathway, thus making it difficult to determine the role of MEG for the purpose of seizure localization.

**Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

Several studies have correlated MEG findings with surgical outcomes. Lau et al (2008) performed a systematic review of 17 such studies. In this review, sensitivity and specificity had unorthodox definitions. Sensitivity was the proportion of patients cured with surgery in whom the MEG-defined epileptic region was resected, and specificity was the proportion of patients not cured with surgery in whom the MEG-defined epileptic region was not resected. Pooled sensitivity was 84%, meaning that, among the total number of cured patients, 16% occurred despite the MEG-defined region not being resected. Pooled specificity was 52%, meaning that, among 48% of patients not cured, the MEG-localized region was resected. These results are consistent with an association between resection of the MEG-defined region and surgical cure, but that it is an imperfect predictor of surgical success. However, it does not address the question whether MEG contributed original information to improve the probability of cure. In a retrospective review of 22 children with medically intractable focal epilepsy (median age at epilepsy surgery, 11 years), Kim et al (2013) used a cutoff of 70% or more for the number of MEG identified spike dipole sources located within the resection margin to define a positive study. Sensitivity, specificity, and positive and negative predictive values for seizure-free status postoperatively were 67%, 14%, 63%, and 17% respectively.

**Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Other studies have implied a value of MEG, but it is difficult to make firm conclusions regarding its value. In a study by Schneider et al (2013), 14 patients with various findings on MEG, IC-EEG, and interictal single-photon emission computed tomography underwent surgery for nonlesional neocortical focal epilepsy. Concordance between IC-EEG and MEG occurred in 5 patients, 4 of whom became seizure-free. This concordance of the 2 tests was the best predictor of becoming seizure-free. Although this was prognostic for success, whether this would actually change surgical decision making, such as declining to operate where there is no such concordance, is uncertain. A similar study by Widjaja et al (2013) showed that concordance between MEG findings and the location of surgical resection correlated with better seizure outcomes. However, the authors acknowledged that MEG was entrenched in clinical practice, and the decision to proceed further in diagnostic and therapeutic endeavors was based on results of MEG and other tests.
Other case series of surgical patients have suggested a value to MEG. A study by Albert et al (2014) reviewed a series of pediatric patients undergoing surgery for epilepsy who had only undergone noninvasive monitoring prior to surgery. MEG was proposed to have avoided the need for the morbidity associated with invasive monitoring. Of 16 patients, 62.5% were seizure-free following surgery, and 20% experienced improvement. Two cases required additional surgery with invasive monitoring. Although most patients improved, it could not be determined whether the outcomes were equivalent to the standard practice of pre-resection invasive monitoring. A study by Wang et al (2015) compared fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET) with MEG in identifying the epileptogenic zone, using invasive monitoring as the reference standard. FDG-PET identified the zone in 8 (50%) of patients and MEG identified the zone in 12 (75%) of patients. Although MEG was more sensitive than FDG-PET in this study, it still missed epileptogenic areas identified by invasive monitoring. Another study, by Koptelova et al (2013), compared MEG with video-EEG monitoring in 22 patients. Of 75 “imitative” zones identified in the 22 patients by either method, a higher proportion was identified by MEG. Note that there is no true reference standard in this type of analysis. However, in analyses of intraoperative EEG, several zones identified only with this method were only identified by MEG, confirming to some extent increased sensitivity over video-EEG. These recent studies have suggested clinical utility for MEG in the evaluation of epilepsy patients, but, due to the aforementioned problems, firm conclusions about the clinical utility of MEG cannot be determined.

The American Clinical Magnetoencephalography Society (2009) released a position statement that supported the routine clinical use of MEG/MSI for presurgical evaluation of patients with medically intractable seizures. This statement cited a study by Sutherling et al (2008) as being a “milestone class I study.” Class I evidence usually refers to randomized comparisons of treatment. However, the authors of Sutherling study described it as a “prospective, blinded crossover-controlled, single-treatment, observational case series.” The study attempted to determine the proportion of patients in whom diagnostic or treatment strategy was changed as a consequence of MEG. They concluded the test provided nonredundant information in 33% of patients, changed treatment in 9% of surgical patients, and benefited 21% of patients who had surgery. There was no control group in this study. The benefit of MEG was inferred by assumptions of what might have occurred in the absence of MEG results. Less than half of 69 enrolled patients went on to receive IC-EEG; thus, there appeared to be incomplete accounting for outcomes of all patients in the study. A similar study by De Tiege et al (2012) also attempted to determine the number of patients in whom management decisions were altered based on MEG results. They concluded that clinical management was altered in 13% of patients.

**Section Summary: Clinically Useful**

Evidence supporting the effect of MEG on patient outcomes is indirect and incomplete. Surgical management may be altered in a minority of patients based on MEG, but the evidence does not support the conclusion that outcomes are improved as a result of these management changes. Trials with a control group are needed to determine whether improved outcomes can be attributed to the change in management induced by knowledge of MEG findings.

**Localization of Eloquent and Sensorimotor Areas**

**Clinical Context and Test Purpose**

The purpose of MEG/MSI in the localization of eloquent and sensorimotor areas of the brain in persons with cortical brain lesions is to create a precise surgical plan for resective procedures to avoid postoperative speech, sensory, and motor dysfunction where possible.

The question addressed in this evidence review is: Does the use of MEG/MSI to map eloquent and sensorimotor brain areas accurately localize these areas and reduce postoperative functional impairment and, thus, result in changes in management and improvement in health outcomes?

The following PICOTS were used to select literature to inform this review.
Patients
The relevant population of interest is patients with brain lesions who are being evaluated for resective surgery.

Interventions
The intervention of interest is the use of MEG/MSI to map eloquent and sensorimotor brain areas. MEG/MSI is a noninvasive alternative to the preoperative Wada test (intracarotid sodium amobarbital procedure) used to map eloquent brain areas.

Comparators
The following test and practice are currently being used to make decisions about localization of eloquent function areas: the Wada test and other standard evaluations.

Outcomes
Outcomes of interest are diagnostic accuracy (e.g., test sensitivity and specificity) and clinical utility (e.g., consideration of avoidance of invasive testing).

Timing
MEG/MSI is used when a patient with a brain lesion in close proximity to eloquent or sensorimotor areas is being evaluated for interventional surgery.

Setting
MEG/MSI is administered in an interdisciplinary specialty care setting.

Technically Reliable
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

A Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Assessment (2003) of MEG/MSI concluded that evidence for this particular indication was insufficient to demonstrate efficacy. At that time, studies reviewed had relatively weak designs and small sample sizes. There are 2 ways to analyze the potential utility of MEG for this indication: MEG could potentially be a noninvasive substitute for the Wada test, which is a standard method of determining hemispheric dominance for language. The Wada test requires catheterization of the internal carotid arteries, which carries the risk of complications. The determination of language laterality is important to know to determine the suitability of a patient for surgery and what types of additional functional testing might be needed before or during surgery. If MEG provided concordant information with the Wada test, then such information would be obtained in a safe, noninvasive manner.

Several studies have shown high concordance between the Wada test and MEG. In the largest study (N=85), Papanicolaou et al (2004) reported concordance between the MEG and Wada tests in 74 (87%) patients. In no cases were the tests discordant in a way that the findings were completely opposite. Discordant cases occurred mostly when the Wada test indicated left dominance and MEG indicated bilateral language function. In an alternative type of analysis, when the test is being used to evaluate the absence or presence of language function in the side in which surgical treatment is being planned, using the Wada procedure as the criterion standard, MEG was 98% sensitive and 83% specific. Thus, if the presence of language function in the surgical site requires intraoperative mapping and/or a tailored surgical approach, use of MEG rather than Wada would have “missed” 1 case where such an approach would be
needed (false-negative MEG), and resulted in 5 cases where such an approach was unnecessary (false-positive MEG). However, it should be noted that the Wada test is not a perfect reference standard, and some discordance may reflect inaccuracy of the reference standard. In another study, Hirata et al (2004) reported that MEG and the Wada test agreed in 19 (95%) of 20 cases.

Section Summary: Clinically Valid
Available evidence comprises studies that correlate the results of MEG with results of the Wada test, which is an alternative method for localization. Evidence has generally shown that concordance between MEG and the Wada test is high. However, the studies have not been replicated and their generalizability is limited.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

One potential use of MEG would be to map the sensorimotor area of the brain to avoid such areas in the surgical resection area. Intraoperative mapping just before resection is generally done as the reference standard. Preoperative mapping as potentially done by MEG might aid in determining the suitability of the patient for surgery or for assisting in the planning of other invasive testing. Similar to the situation for localization of epilepsy focus, the literature is problematic in terms of evaluating the comprehensive outcomes of patients due to ascertainment and selection biases. Studies tend to be limited to correlations between MEG and intraoperative mapping. Intraoperative mapping would be performed anyway in most resection patients. Several studies evaluated in the TEC Assessment (2003) showed good to high concordance between MEG/MSI findings and intraoperative mapping. A technology assessment of functional brain imaging prepared by the Ontario Ministry of Health (2006) reviewed 10 studies of MEG and invasive functional mapping and showed good to high correspondence between the 2 tests. However, these studies did not demonstrate that MEG would replace intraoperative mapping or reduce the morbidity of such mapping by allowing a more focused procedure.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Studies of the use of MEG in localizing the sensorimotor area provide only indirect evidence of utility. Niranjan et al (2013) reviewed the results of 45 patients in whom MEG was used for localizing the somatosensory function. In 32 patients who underwent surgery, surgical access routes were planned to avoid regions identified as somatosensory by MEG. All patients retained somatosensory function. It is unknown to what extent MEG provided unique information not provided by other tests. In a study by Tarapore et al (2012), 24 patients underwent MEG, transcranial magnetic stimulation, and intraoperative direct cortical stimulation to identify the motor cortex. MEG and navigated transcranial magnetic stimulation both identified several areas of motor function and the median distance between corresponding motor areas was 4.71 mm. When comparing MEG with direct cortical stimulation, median distance between corresponding motor sites (12.1 mm) was greater than the distance between navigated transcranial magnetic stimulation and direct cortical stimulation (2.13 mm). This study did not
determine whether MEG provided unique information that contributed to better patient outcomes.

Section Summary: Clinically Useful
There are no clinical trials that demonstrate the clinical utility of using MEG for localization and lateralization of eloquent and sensorimotor regions of the brain. Because MEG is a less invasive alternative to the Wada test, this evidence indicates that it is a reasonable alternative. There is also some evidence that the correlation between MEG and intraoperative mapping of eloquent and sensorimotor regions is high, but the test has not demonstrated sufficient accuracy to replace intraoperative mapping.

Summary of Evidence
For individuals who have drug-resistant epilepsy and are being evaluated for possible resective surgery who receive MEG/MSI, the evidence for MEG/MSI as an adjunct to standard clinical workup includes various types of case series. Relevant outcomes are test accuracy and functional outcomes. Published evidence on MEG is suboptimal, with no clinical trials demonstrating clinical utility. The literature on diagnostic accuracy has methodologic limitations, primarily selection and ascertainment bias. Studies of functional outcomes do not fully account for the effects of MEG, because subjects who received MEG were not fully accounted for in the studies. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a planned brain resection who require localization of eloquent function areas who receive MEG/MSI, the evidence includes comparative studies. Relevant outcomes include test accuracy and functional outcomes. Available studies have reported that this test has high concordance with the Wada test, which is currently the main alternative to localize eloquent functions. While management is changed in some patients based on MEG testing, it has not been demonstrated that these changes lead to improved outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Clinical Input from Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests from Blue Cross Blue Shield Association, input was received from 2 physician specialty societies (5 reviewers) and 2 academic medical centers in 2011. There was support for use of magnetoencephalography and magnetic source imaging for localization of language function and as part of the preoperative evaluation of intractable seizures. Those providing input indicated that use of magnetoencephalography and magnetic source imaging in the preoperative evaluation leads to the identification of additional people whose epilepsy may be cured using a surgical approach.

Practice Guidelines and Position Statements
American Clinical Magnetoencephalography Society
The American Clinical Magnetoencephalography Society (2009) released a position statement supporting routine clinical use of magnetoencephalography (MEG) plus magnetic source imaging for presurgical evaluation of patients with medically intractable seizures (see Rationale section).14

The Society (2011) issued a series of practice guidelines on magnetic evoked fields addressing different aspects of this technology (recording and analysis of spontaneous cerebral activity,23 presurgical functional brain mapping using magnetic evoked fields,24 MEG and
electroencephalogram reporting, and qualifications of MEG-electroencephalogram personnel. Methods of guideline development were not described.

Guideline 2 on presurgical functional brain mapping indicated that:

“Magnetoencephalography shares with EEG high temporal resolution, but its chief advantage in pre-surgical functional brain mapping is in its high spatial resolution. Magnetic evoked fields are therefore done for localization; unlike electrical evoked potentials (EPs), [magnetic evoked fields] latencies and latency asymmetries are not typically used to detect abnormalities.”

Proposed indications for MEG included localization of somatosensory, auditory, language, and motor evoked fields.

The Society (2017) issued another position statement supporting the routine use of MEG/MSI for obtaining noninvasive localizing or lateralizing information regarding eloquent cortices (somatosensory, motor, visual, auditory, and language) in the presurgical evaluation of patients with operable lesions preparing for surgery.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Movement disorders</td>
<td>Defining Cognitive and Motor Phenotypes of Parkinson's Disease (PD) With Magnetoencephalography</td>
<td>18</td>
<td>Dec 2018</td>
</tr>
<tr>
<td>Unpublished Cognition</td>
<td>Functional Brain Imaging in Healthy Volunteers to Study Cognitive Functions</td>
<td>154 (completed)</td>
<td></td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References
3. Food and Drug Administration. Section 510(k) Premarket Notification K152184 MagView Biomagnetometer. 2016;


17. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Magnetoencephalography (MEG) and magnetic source imaging (MSI): presurgical localization of epileptic lesions and presurgical function mapping. TEC Assessments. 2003;Volume 18:Tab 6.


**Documentation for Clinical Review**

Please provide the following documentation (if/when requested):
- History and physical from referring physician and/or consultation notes including:
  - Previous treatment plan and response
  - Diagnostic imaging reports, if applicable

**Post Service**
- Magnetoencephalography or magnetic source imaging report

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>95965</td>
<td>Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)</td>
</tr>
<tr>
<td></td>
<td>95966</td>
<td>Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)</td>
</tr>
</tbody>
</table>
### Type | Code | Description
--- | --- | ---
 | 95967 | Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)
 | S8035 | Magnetic source imaging
 | None | None

### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/2005</td>
<td>Administrative Review</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>04/05/2007</td>
<td>Policy Revision</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>09/12/2008</td>
<td>Policy Revision Policy revision</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>10/07/2011</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>07/14/2014</td>
<td>Policy revision with position</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>02/27/2015</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>04/01/2016</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>06/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>11/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>11/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

### Definitions of Decision Determinations

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.
Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.